Pulmonary arterial hypertension remains a progressive, life-limiting disease despite optimal medical therapy. Pulmonary artery denervation has arisen as a novel intervention in the treatment of pulmonary arterial hypertension, and other forms of pulmonary hypertension, with the aim of reducing the sympathetic activity of the pulmonary circulation. Pre-clinical studies and initial clinical trials have demonstrated that the technique can be performed safely with some positive effects on clinical, haemodynamic and echocardiographic markers of disease. The scope of the technique in current practice remains limited given the absence of well-designed, large-scale, international randomised controlled clinical trials. This review provides an overview of this exciting new treatment modality, including pathophysiology, technical innovations and recent trial results.

尽管进行了最佳药物治疗，肺动脉高压仍然是一种进行性的、限制生命的疾病。肺动脉去神经支配已成为治疗肺动脉高压和其他形式的肺动脉高压的新型干预措施，其目的是降低肺循环的交感神经活动。临床前研究和初步临床试验表明，该技术可以安全地进行，并对疾病的临床、血液动力学和超声心动图标志物产生一些积极影响。鉴于缺乏精心设计的大规模国际随机对照临床试验，该技术在当前实践中的范围仍然有限。本综述概述了这种令人兴奋的新治疗方式，包括病理生理学、